ClinicalTrials.gg
RecruitingNCT06648278COUNTS2Updated Jan 13, 2026

Patient Care Outreach, Navigation, Technology and Support 2.0

An interventional study of Patient Navigation Program and Quality-of-Life (QOL) Assessment in Breast Cancer and Cardiovascular Diseases, sponsored by University of California, San Francisco. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2023, registered Oct 2024).
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Planned enrollment
7th of 49
260 · median 38
Started
2023
with 4 others
No phase
23 of 62
4 open now
Primary completion
2027-02
later than 3 of 15 live
Registered
56th of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 7th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2023, is one of 23 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 56th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This is a feasibility study employing virtual patient navigation for underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer or cardiovascular disease to determine the extent of usability for a virtual patient navigation portal serving people in underserved communities. While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.

Read the detailed description

Patient COUNTS 2.0 aims to improve and scale up the current Patient COUNTS program.

PRIMARY OBJECTIVES:

I. Identify underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer or cardiovascular disease through collaboration with Zuckerberg San Francisco General Hospital (ZSFG), University of California, San Francisco clinics (Athena), University of California, San Francisco registries (via medical chart review), San Francisco State University, and other community organization collaborators.

II. Conduct outreach to potential participants to let them know about the availability of virtual patient navigation via the Patient Care Outreach, Navigation, Technology and Support (COUNTS) web portal, and the Patient COUNTS patient navigation program (NCT03867916).

III. Provide patient navigation virtually.

OUTLINE:

The patient COUNTS portal will be available in English and expanded to include content in Chinese and Spanish. An initial cohort of focus group of 15 breast cancer patients, 5 navigators, social workers, caregivers or other person involved in breast cancer care will help develop the culturally and language specific components of the COUNTS program. Following implementation, breast cancer participants and cardiovascular participants will participate in an online navigation program along with family members of the patient community will be enrolled. Participants will use the online COUNTS portal to access navigation program and may choose to have online/virtual navigation support or in-person navigation support. Participants also complete data collection and surveys over 15 minutes via web portal at baseline and 6 months and user experience survey at end of program participation.

03

Conditions studied

  • Breast Cancer
  • Cardiovascular Diseases

Keywords

  • Health Services
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Focus groups:

  • Breast cancer patients: Diagnosed with breast cancer, ages 18 or older, speaks English, Mandarin/Cantonese, or Spanish
  • Navigators: any patient navigator who has provided care to underserved populations diagnosed with cancer

For Portal Implementation phase:

  • Ages 18 or older
  • Speaks English, Mandarin/Cantonese, Spanish,
  • Has any stage breast cancer
  • Has access to a phone that is able to receive text messages, is willing to stay in the study for six-seven months.

Family User experience survey:

  • Family member or friend who may have assisted breast cancer participant with registration, accessing or otherwise assisting breast cancer family member or friend participant with the online portal.

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychological conditions precluding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Health services research (Patient COUNTS2)

    Participants attend focus groups to help further develop the patient portal and navigation program to expand to other groups. Participants use in-person navigation program and complete data collection and surveys over 15 minutes via web portal at baseline and 6 months and user experience survey at end of program participation.

    Behavioral: Patient Navigation Program · Other: Quality-of-Life (QOL) Assessment · Other: Survey Administration

Interventions

  • BehavioralPatient Navigation Program

    Online health tool

    Also known as: Patient Navigator Program

  • OtherQuality-of-Life (QOL) Assessment

    Online surveys to assess QOL

    Also known as: QOL Assessment, QOL Survey

  • OtherSurvey Administration

    Ancillary studies

    Also known as: Experience Survey

06

What researchers measure

Primary outcomes

  1. Proportion of participants who reported satisfaction with COUNTS program

    Participant satisfaction will be assessed via a response of "satisfied" or "very satisfied" to survey item on satisfaction with Patient COUNTS navigation program

    Time frame: Up to 6 months

  2. Rate of Participation

    Participation is defined as having at least one contact with patient navigator

    Time frame: Up to 6 months

  3. Utilization rate

    Utilization is defined as the number of interactions with the patient navigator

    Time frame: Up to 6 months

Secondary outcomes

  1. Mean scores on the Functional Assessment of Cancer Therapy- Breast (FACT-B)

    The FACT-B is a self-report instrument that measures multidimensional quality of life (QOL) in patients with breast cancer. The FACT-B consists of 37 questions that address physical, social, emotional, and functional well-being, with specific questions relevant to women with breast cancer. Each item has a score range of 0 (Not at all) to 4 (Very much), with a total score ranging from 0-148. The higher the score, the better the QOL reported by the participant.

    Time frame: Up to 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Feb 2027, 42 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 42 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 18, 2024
StartActual
Aug 10, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648278
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Aug 10, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Laura Allen
Contact
Laura.Allen@ucsf.edu
415-818-7143
Scarlett L Gomez, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion